Aerie Pharmaceuticals Inc PER
¿Qué es el PER de Aerie Pharmaceuticals Inc?
El PER de Aerie Pharmaceuticals Inc es 0.00
¿Cuál es la definición de PER?
La relación precio/ganancias es la relación entre el precio de las acciones de una compañía y las ganancias por acción de la compañía calculadas en los últimos doce meses.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
PER de compañías en Sector Health Care en NASDAQ en comparadas con Aerie Pharmaceuticals Inc
¿Qué hace Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Empresas con per similar a Aerie Pharmaceuticals Inc
- Richland Resources International tiene PER de N/A
- Safeplus International tiene PER de N/A
- China Yanyuan Yuhui Natl Ed Grp tiene PER de N/A
- Acusphere tiene PER de N/A
- American Oriental Bioengineering tiene PER de N/A
- Gourmet Provisions International tiene PER de N/A
- Aerie Pharmaceuticals Inc tiene PER de 0.00
- SEL Manufacturing tiene PER de 0.00
- China Zhong Qi Hldgs tiene PER de 0.00
- MedSmart tiene PER de 0.00
- Panbela Therapeutics tiene PER de 0.00
- Epic tiene PER de 0.00
- 2574 tiene PER de 0.00